KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Return on Equity (2016 - 2025)

Historic Return on Equity for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to 0.09%.

  • Biomarin Pharmaceutical's Return on Equity rose 300.0% to 0.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.09%, marking a year-over-year increase of 300.0%. This contributed to the annual value of 0.08% for FY2024, which is 500.0% up from last year.
  • As of Q3 2025, Biomarin Pharmaceutical's Return on Equity stood at 0.09%, which was up 300.0% from 0.11% recorded in Q2 2025.
  • Biomarin Pharmaceutical's 5-year Return on Equity high stood at 0.2% for Q2 2021, and its period low was 0.02% during Q4 2021.
  • Over the past 5 years, Biomarin Pharmaceutical's median Return on Equity value was 0.03% (recorded in 2023), while the average stood at 0.06%.
  • Over the last 5 years, Biomarin Pharmaceutical's Return on Equity had its largest YoY gain of 1600bps in 2021, and its largest YoY loss of -2300bps in 2021.
  • Over the past 5 years, Biomarin Pharmaceutical's Return on Equity (Quarter) stood at 0.02% in 2021, then skyrocketed by 306bps to 0.03% in 2022, then rose by 10bps to 0.03% in 2023, then surged by 126bps to 0.08% in 2024, then increased by 12bps to 0.09% in 2025.
  • Its Return on Equity stands at 0.09% for Q3 2025, versus 0.11% for Q2 2025 and 0.09% for Q1 2025.